325% rally in five years! Multibagger pharma stock in focus; here's why
Multibagger stock: Pharma company Sudarshan Pharma Industries share price will remain in focus in Monday's trading session after the company reported its half yearly and FY25 financial & operational performance on Friday.
The multibagger pharma stock was down 1.99 per cent to close at ₹ 26.66 apiece on May 2. Sudarshan Pharma Industries shares have given mutlibagger returns to its investors by soaring over 325 per cent in five years.
In the second half of FY25 (H2FY25), Sudarshan Pharma Industries Limited (SPIL) reported a 19% rise in net sales to ₹ 277 crore and a 43% increase in net profit to ₹ 7 crore compared to H2FY24.
For the full fiscal year FY25, net sales rose by 9% to ₹ 505 crore, while net profit surged by 45% to ₹ 16 crore year-on-year. The company, currently valued at ₹ 642 crore in market capitalization, has achieved a strong compound annual profit growth of 37% over the past five years.
SPIL is actively working to boost its exports and increase domestic sales of its manufactured medicines, the pharma company said in its investor's presentation. Additionally, it aims to improve profit margins from reselling Active Pharmaceutical Ingredients (API) in India.
This strategic focus contributed to a significant rise in EBITDA margin in H2FY25, which in turn drove strong growth in Profit After Tax during the same period.
India's pharmaceutical industry was valued at approximately $42 billion in 2021 and is projected to rise to around $50 billion by 2024. Forecasts suggest it could reach nearly $66 billion by 2025 and potentially expand to between $120 billion and $130 billion by 2030.
India fulfills 40% of the United States' generic drug requirements and supplies 25% of the medicines used in the United Kingdom. Globally, India contributes 20% of total medicine production by volume and meets about 60% of the world's vaccine demand, solidifying its position as the leading supplier of generic drugs.
Founded in 2008, Sudarshan Pharma is engaged in manufacturing and sourcing of Chemicals and Pharmaceutical products. The Company specializes in host of products from rock chemicals intermediates and API to finish formulations and fully integrated pharmaceutical and chemicals.
Disclaimer: This story is for educational purposes only. The views and recommendations above are those of individual analysts or broking companies, not Mint. We advise investors to check with certified experts before making any investment decisions.
First Published: 4 May 2025, 01:51 PM IST
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
&w=3840&q=100)
Business Standard
13 hours ago
- Business Standard
Tata Steel plans to commission UK electric arc furnace unit by 2027
Tata Steel plans to begin construction of its low-carbon electric arc furnace (EAF) steelmaking facility in the UK in July 2025, with operations scheduled to begin in 2027, the company said in its financial year 2024–25 (FY25) annual report. 'Using recycled scrap, the new (Port Talbot plant) steelmaking facility will reduce the on-site carbon emissions by up to 90 per cent,' the company said in its annual report. The EAF is scheduled to become fully operational by 2027, with an annual production capacity of 3.2 million tonnes of low-emission steel. The EAF-based steelmaking project is projected to cut more than 50 million tonnes of carbon dioxide emissions over the next ten years. The company stated that the structural transition is being carried out alongside a major focus on cost rationalisation. The company aims to reduce its fixed costs from £762 million in FY25 to £540 million in the following year. Performance and investment 'The recently acquired entity Neelachal Ispat Nigam Limited delivered a strong performance with ₹1,000 crore in EBITDA and positive free cash flows,' N Chandrasekaran, chairman, Tata Steel, said. 'On a consolidated basis, in FY2024–25, Tata Steel's crude steel production reached 30.92 million tonnes, while deliveries grew to 30.96 million tonnes (an increase of 3.3 per cent and 5.3 per cent y-o-y, respectively), both marking new highs,' the chairman added. Climate goals Tata Steel targets a 10–15 per cent reduction in emission intensity by 2030, compared to levels in FY2024–25. Tata Steel is constructing a 0.75 MTPA scrap-based electric arc furnace in Ludhiana to address expected medium- to long-term demand for low-emission steel in India. The company is also evaluating technologies to decarbonise its value chain. In addition, it has launched India's first Carbon Bank to convert carbon dioxide into value-generating assets for customers. Tata Steel became the first Indian steel company to demonstrate end-to-end capabilities in developing hydrogen transportation pipes. 'In January 2025, the company successfully developed and tested API X65 Electric Resistance Welded (ERW) pipes, using steel manufactured at its Kalinganagar plant and processed at Khopoli,' the company said. API X65 Grade pipes transport 100 per cent pure gaseous hydrogen under high pressure. Tech The company has deployed more than 558 artificial intelligence (AI) models in key areas including process control, predictive and prescriptive maintenance, procurement analytics, boulder detection at mining sites, and integrated operational management during FY25. 'Supply chain solutions like Compass in India and Nexus in Europe help streamline operations by providing better visibility of material flow through the supply chain to the customers. The Integrated Remote Operations Centre (i-ROC) empowers remote supervision and plant operations management,' the company said.
Business Standard
3 days ago
- Business Standard
Carbogen Amic AG to co-invest in its manufacturing sites in Switzerland
Dishman Carbogen Amcis' wholly owned subsidiary, CARBOGEN AMCIS AG, a pharmaceutical process development and Active Pharmaceutical Ingredient (API) and drug products manufacturing company, announced a strategic co-investment of more than CHF 25 million with a long-standing Japanese customer to expand manufacturing capabilities at its sites in Aarau and Neuland, Switzerland. The investment will support the production of a drug linker for a commercial antibody-drug conjugate (ADC), enabling CARBOGEN AMCIS to meet rising global demand. As part of the agreement, both facilities will see significant equipment and infrastructure enhancements, including: Aarau site: installation of 850-litre reactors and 0.4 m agitated filter dryers with supporting equipment. Completion is expected by Q1 2027. Neuland site: installation of 850-litre reactors and 0.4 m agitated filter dryers with auxiliary systems. Completion is anticipated by Q3 2027. This project builds on a previous joint funding agreement between CARBOGEN AMCIS and the same customer in April 2021 to develop a site extension at the Bubendorf site in Switzerland, reinforcing the strength of the relationship and their shared commitment to long-term growth.
Hans India
3 days ago
- Hans India
OpenAI Academy Set to Launch in India Under MoU with IndiaAI Mission
In a landmark move to strengthen AI education and innovation in India, OpenAI has signed a memorandum of understanding (MoU) with the Indian government's IndiaAI Mission to launch the OpenAI Academy—marking its first international rollout. As part of this collaboration, OpenAI and IndiaAI will jointly deliver curated artificial intelligence (AI) training content via the OpenAI Academy and the IndiaAI FutureSkills portal. These offerings will be accessible to a wide audience, including public sector professionals, in multiple languages—English, Hindi, and four regional languages—ensuring inclusivity in skill-building. Jason Kwon, Chief Strategy Officer at OpenAI, emphasized India's key role in the global AI landscape, stating, 'With the second-largest number of ChatGPT users, India ranks among the top countries actively building AI technologies.' Speaking at the launch event, Abhishek Singh, CEO of IndiaAI Mission, identified one of India's critical hurdles in AI development: access to computing power. 'This has been addressed by providing around 34,000 GPUs at affordable rates—less than a dollar per GPU hour—significantly lower than global prices,' he said. In addition to computational resources, Singh also spotlighted the AI Kosh platform, which offers a rich repository of datasets across sectors, along with essential tools, AI models, and a sandbox environment to encourage innovation. Through a virtual message, Union Minister Ashwini Vaishnaw described the initiative as a milestone for the country. 'This partnership is a significant step towards advancing our shared goal of democratizing access to knowledge and technology,' he said. This launch follows Kwon's global tour to engage with international policymakers on responsible AI deployment and governance. The academy initiative in India is aligned with OpenAI's broader commitment to make AI education globally accessible and responsible. In a move reflecting its growing investment in the Indian market, OpenAI last month introduced local data residency for Indian users. This ensures that data from ChatGPT Enterprise, ChatGPT Edu, and the OpenAI API platform will now be stored within the country, addressing key regulatory and privacy concerns. Further expanding its impact, OpenAI also announced the extension of its AI for Impact Accelerator Program to India. As part of this phase, 11 nonprofit organizations in the country have been selected to receive API credits and technical grants totaling $150,000. This initiative is backed by philanthropic partners including The Agency Fund, Tech4Dev, and These selected nonprofits will gain access to hands-on technical mentorship, cohort-based learning programs, and early access to OpenAI tools—empowering them to develop AI-driven solutions for social challenges. By combining educational outreach, infrastructure support, and social impact investment, OpenAI's partnership with IndiaAI is poised to significantly boost India's AI capabilities, while also ensuring that AI development remains inclusive, ethical, and transformative.
